A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

Wu C.; Mikhail S.; Wei L.Timmers C.Tahiri S.Neal A.Walker J.El-Dika S.Blazer M.Rock J.Clark D. J.Yang X.Chen J. L.Liu J.Knopp M. V.Bekaii-Saab T.

首页> 外文期刊>The British journal of cancer >A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

【24h】

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

机译：在复发/难治性食道和胃o鼠癌中舒尼替尼的II期和药效学研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Blockade of the vascular endothelial growth factor (VEGF) pathway shows evidence of activity in gastro-oesophageal (GE) and oesophageal cancer. We investigated the efficacy of sunitinib, a multikinase VEGF inhibitor, in patients with relapsed/refractory GE/oesophageal cancer.

机译：背景：封锁血管内皮生长因子（VEGF）途径显示出胃植进（GE）和食管癌活性的证据。我们研究了复发/难治性GE/食管癌的患者Sunitinib（一种多次激酶VEGF抑制剂）的疗效。

著录项

来源
《The British journal of cancer 》 |2015年第2期| 220-225| 共6页
作者
Wu C.; Mikhail S.; Wei L.Timmers C.Tahiri S.Neal A.Walker J.El-Dika S.Blazer M.Rock J.Clark D. J.Yang X.Chen J. L.Liu J.Knopp M. V.Bekaii-Saab T.;
展开▼
作者单位

Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Div Med Oncol,Dept Internal Med;

Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Columbus, OH;

Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Dept Biomed Informat,Div Med OncolBeaumont Med Ctr, Dept Pathol, Grosse Pointe, MI USAOhio State Univ, Wexner Med Ctr, Dept Pharm, Columbus, OH 43210 USAMercy Anderson Hosp, Anat Pathol Lab, Cincinnati, OH 43210 USAOhio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USAOhio State Univ, Wexner Med Ctr, Dept Radiol, Columbus, OH 43210 USAOhio State Univ, Ctr Comprehens Canc, Ctr Biostat, Columbus, OH 43210 USA;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词
Endothelial Growth Factors; sunitinib; Cancer of EsophagusComplement Factor B;

机译：内皮生长因子;舒尼替尼;食管结束因子B癌B;

相似文献

外文文献
中文文献

1. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma [J] . Yun Leng, Wenming Chen, Lugui Qiu, 癌症（英文版） . 2016 ,第012期

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

摘要

著录项

相似文献

相关主题

期刊订阅